Clinical Trials Browser

Phase 2/3 × Carcinoma, Hepatocellular × Nivolumab × Clear all

NCT04268888 2025-02-26

TACE-3

Phase 2/3 Suspended

Gastrointestinal

Carcinoma, Hepatocellular

NCT04044651 2020-01-09

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Phase 2/3 Withdrawn

Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular